Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal second quarter 2025 results through the filing of its Form 10-Q. Since our previous update, the company has made progress with its multiple ...

As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated ...

Lexaria’s after-hours surge came after the company filed with the Securities and Exchange Commission on Thursday, revealing that it had ended its “Capital on Demand” Sales Agreement with JonesTrading ...

(RTTNews) - Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that ...